Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Aprea Therapeutics ( (APRE) ) has shared an update.
On May 13, 2026, Aprea Therapeutics reported first-quarter 2026 results and a corporate update, highlighting clinical progress for WEE1 inhibitor APR-1051 in the Phase 1 ACESOT-1051 trial, including two partial responses and generally favorable tolerability among 28 treated patients. Supported by an oversubscribed $30 million private placement closed on March 31, 2026, the company plans to expand enrollment to at least 50 uterine serous carcinoma patients and additional platinum-resistant ovarian cancer patients, with dose escalation continuing into 2027 and new data due at the ASCO 2026 meeting.
Aprea also reported that ATR inhibitor ATRN-119 reached a recommended Phase 2 dose in 2025, but the ABOYA-119 monotherapy trial has been strategically paused while the company explores combination approaches with radiation, immuno-oncology agents and antibody-drug conjugates. Financially, cash and cash equivalents rose to $46.5 million as of March 31, 2026, extending the projected runway into the first quarter of 2028, while quarterly operating loss narrowed to $3.4 million, aided by reduced R&D spending following the voluntary pause of the ATRN-119 monotherapy trial and steady G&A expenses.
The most recent analyst rating on (APRE) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Aprea Therapeutics stock, see the APRE Stock Forecast page.
Spark’s Take on APRE Stock
According to Spark, TipRanks’ AI Analyst, APRE is a Neutral.
The score is held down primarily by weak financial performance (ongoing losses, negative cash flow, and zero revenue in 2025). Technicals have improved in the near term (positive momentum and price above key short/mid-term averages), and recent financing/early clinical updates are supportive, but valuation support is limited due to negative earnings and no dividend data.
To see Spark’s full report on APRE stock, click here.
More about Aprea Therapeutics
Aprea Therapeutics, Inc. is a clinical-stage precision medicine oncology company focused on discovering and developing targeted therapies for patients with biomarker-defined cancers. Its lead programs include APR-1051, an oral WEE1 inhibitor for difficult-to-treat solid tumors, and ATRN-119, a macrocyclic ATR inhibitor aimed at tumors with DNA damage response gene mutations.
The company targets patient populations with high unmet medical need, such as uterine serous carcinoma, platinum-resistant ovarian cancer, colorectal cancer with specific mutations, and HPV-positive head and neck cancers. Aprea is listed on Nasdaq under the ticker APRE and is positioning itself within the oncology space through biomarker-driven trial designs and selective capital deployment.
Average Trading Volume: 457,305
Technical Sentiment Signal: Sell
Current Market Cap: $11.14M
Find detailed analytics on APRE stock on TipRanks’ Stock Analysis page.